Novartis begins clinical study of Roksolana in patients with severe COVID-19

Novartis has announced plans to begin clinical trials by phase III, which will help assess the effectiveness of the drug rukolaine for the treatment of severe forms of excessive reactions of the immune system known as cytokine storm. For patients with COVID-19 this condition can lead to life-threatening complications of the respiratory system. Research will be conducted in collaboration with pharmaceutical Incyte Corporation.

Novartis took a decision to review the operation of Roksolana for a new drug indication based on preclinical and preliminary clinical data as well as on verified information about the safety and efficacy of the drug in case of acute “graft versus host” and myeloproliferative malignancy in a patient. The study will assess the effectiveness of Roksolana in combination with standard therapy compared to standard therapy alone in patients with severe pneumonia COVID-19.

Roksolani is an oral inhibitor of the tyrosine kinases JAK1 and JAK2. The drug is approved by the European Commission for the treatment of adult patients with polycythemia Vera (SP) resistant to hydroxyurea, or in the case of intolerance, as well as for treatment due to disease splenomegaly or symptoms in adult patients with primary myelofibrosis (MF), MF after polycythemia Vera or essential thrombocythemia. For the treatment of MF rukolaine approved in 101 countries, and for the treatment of polycythemia Vera – in more than 75 countries, including Russia. Specific indications for the drug rukolaine in different countries may vary. Regulatory bodies worldwide continue to be new applications of MF and IE.

Leave a Reply

Your email address will not be published. Required fields are marked *


For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]